Study Title and Clinical Context
Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial
This article summarizes a prespecified subgroup analysis from the VESALIUS-CV trial, focused on people who had previously undergone percutaneous coronary intervention (PCI) but had never had a myocardial infarction (MI, or heart attack). PCI includes procedures such as balloon angioplasty and stent placement, which are used to open narrowed coronary arteries. Although these patients have documented coronary artery disease, it has not been fully clear whether very intensive LDL-C lowering with evolocumab meaningfully reduces future cardiovascular events in this specific group.
Why This Question Matters
Cardiovascular disease remains a leading cause of death worldwide. Even after a successful PCI, patients remain at risk for recurrent ischemic events because the underlying atherosclerotic disease can continue to progress. Low-density lipoprotein cholesterol (LDL-C), often called “bad cholesterol,” plays a central role in plaque buildup and rupture. Lowering LDL-C more aggressively generally lowers cardiovascular risk, but the benefit can vary depending on the patient’s baseline risk and clinical history.
Evolocumab is a monoclonal antibody that inhibits PCSK9, a protein that normally reduces the liver’s ability to remove LDL-C from the bloodstream. By blocking PCSK9, evolocumab can substantially lower LDL-C levels, often by 50% to 60% on top of standard therapy. The key clinical question is not only whether LDL-C falls, but whether that reduction translates into fewer heart attacks, strokes, revascularizations, and deaths in patients who have already undergone PCI but have not yet had an MI.
Study Design
VESALIUS-CV randomized patients with atherosclerosis or high-risk diabetes who had no prior MI or stroke and had LDL-C levels of at least 90 mg/dL to receive either evolocumab or placebo, in addition to usual care. The median follow-up was 4.6 years.
For this prespecified subgroup analysis, participants were divided according to whether they had undergone PCI at any time before entering the trial. This is clinically important because prior PCI identifies a patient with established coronary artery disease, but not all such patients have the same future risk profile. Some may have had PCI for stable angina rather than an acute coronary syndrome, and therefore they may not have a prior MI in their history.
The trial had two dual primary endpoints:
1. 3-point major adverse cardiovascular events (MACE): coronary heart disease death, MI, or ischemic stroke
2. 4-point MACE: the above composite plus ischemia-driven arterial revascularization
This broader composite helps capture not only fatal and nonfatal events but also clinically meaningful procedures that indicate worsening coronary disease.
Who Was Included
Among 12,257 randomized patients, 3,627, or about 29.6%, had a history of PCI before trial enrollment. The median time between the PCI procedure and entry into the study was 4 years, showing that many participants were clinically stable rather than in the immediate post-procedure period.
In this prior-PCI subgroup:
– Median age was 66 years
– 30.7% were women
This demographic profile is typical of an older, high-risk cardiovascular population. Although the subgroup had already undergone an intervention on the coronary arteries, they still had enough residual risk to justify evaluation of long-term preventive therapy.
LDL-C Lowering Achieved With Evolocumab
Evolocumab produced a large and sustained LDL-C reduction. At 48 weeks, the median LDL-C level was 41.5 mg/dL in the evolocumab group compared with 107.0 mg/dL in the placebo group, a highly significant difference.
This degree of reduction is clinically meaningful. In cardiovascular prevention, lower LDL-C levels are associated with lower event rates, especially when the reduction is maintained over years. The results also reinforce the idea that patients who start with moderately elevated LDL-C may still benefit substantially from further lowering, even when already receiving background therapy.
Main Clinical Results
In patients with prior PCI, evolocumab reduced the risk of major cardiovascular events across several important outcomes.
For 3-point MACE:
– 5-year Kaplan-Meier event rate: 7.0% with evolocumab vs 9.5% with placebo
– Hazard ratio: 0.70
– 95% confidence interval: 0.56 to 0.89
– P = 0.004
This represents a 30% relative risk reduction.
For 4-point MACE:
– 5-year Kaplan-Meier event rate: 17.9% with evolocumab vs 21.7% with placebo
– Hazard ratio: 0.82
– 95% confidence interval: 0.71 to 0.96
– P = 0.012
This represents an 18% relative risk reduction.
The benefit was not limited to composite outcomes. Evolocumab also reduced:
– Myocardial infarction by 50%: 3.0% vs 6.1%; hazard ratio 0.50; 95% CI 0.36 to 0.70; P < 0.001
– Urgent coronary revascularization by 39%: hazard ratio 0.61; 95% CI 0.46 to 0.80; P < 0.001
Notably, the treatment effect on MI became apparent as early as 6 months after randomization, suggesting that the benefit of intensive LDL-C lowering may begin relatively soon after treatment initiation rather than requiring many years to emerge.
There were also numerically lower rates of:
– Cardiovascular death: 2.6% vs 3.7%; hazard ratio 0.66; 95% CI 0.45 to 0.96; P = 0.030
– All-cause death: 8.2% vs 10.2%; hazard ratio 0.76; 95% CI 0.60 to 0.95; P = 0.016
These mortality findings are encouraging, although they are described as nominally lower rates and should be interpreted within the broader statistical context of subgroup analyses.
What the Results Mean
The central message is that patients with prior PCI but no prior MI still benefit from intensive LDL-C lowering with evolocumab. This is important because some clinicians may consider such patients “stable” or lower risk than patients with prior MI, leading to less aggressive lipid-lowering therapy. The VESALIUS-CV subgroup data suggest that this group remains at substantial residual risk and can gain meaningful protection from additional LDL-C reduction.
From a practical standpoint, these findings support a more proactive prevention strategy in patients who have undergone PCI, even when they have not had a documented heart attack. A prior PCI is not simply a historical procedure; it is a marker of established coronary atherosclerosis and ongoing future risk.
Clinical Implications for Care
These findings may influence how clinicians think about long-term secondary prevention after PCI. Standard care after PCI typically includes antiplatelet therapy, blood pressure control, smoking cessation, diabetes management, lifestyle modification, and statin therapy when indicated. For patients who remain above guideline LDL-C targets despite statins, adding ezetimibe or a PCSK9 inhibitor such as evolocumab can be considered.
The study strengthens the rationale for considering evolocumab in patients who:
– Have known coronary artery disease and prior PCI
– Have no prior MI or stroke
– Continue to have elevated LDL-C despite background therapy
– Are at sufficiently high risk to justify intensive lipid lowering
The results also reinforce an important preventive principle: waiting for a first MI before intensifying therapy may miss an opportunity to prevent serious events in patients who already have significant coronary disease.
How Evolocumab Works
Evolocumab is given by injection and targets PCSK9, a protein that leads to degradation of LDL receptors in the liver. More LDL receptors on liver cells means more LDL-C can be removed from the blood. This mechanism makes PCSK9 inhibitors a powerful tool when statins alone do not achieve adequate LDL-C lowering.
In real-world practice, evolocumab is often used when:
– Statins are not enough to reach LDL-C goals
– Patients cannot tolerate high-intensity statin doses
– Risk remains high despite combination therapy
The VESALIUS-CV findings add to the evidence that lowering LDL-C with a PCSK9 inhibitor is not just a laboratory improvement; it can translate into fewer hard cardiovascular events.
Strengths and Limitations
A major strength of this analysis is that it was prespecified, which means the investigators planned it in advance rather than searching for it after seeing the data. The follow-up period was also relatively long, allowing enough time to observe clinically meaningful outcomes.
However, subgroup analyses always have limitations. They are not the same as a trial designed specifically for one subgroup, and results should be viewed in the context of the full trial population. In addition, the study population was selected for elevated LDL-C and high cardiovascular risk, so the findings may not apply equally to lower-risk patients or those already at very low LDL-C levels.
Another important consideration is cost, access, and injection burden, which can affect real-world use of PCSK9 inhibitors even when clinical benefit is clear.
Bottom Line
In stable patients with prior PCI but no prior MI, evolocumab substantially lowered LDL-C and reduced major cardiovascular events, including MI and urgent coronary revascularization. These results support intensive LDL-C lowering as an effective prevention strategy in patients with established coronary artery disease, even when they have not experienced a heart attack.
For clinicians and patients, the key takeaway is straightforward: a history of PCI alone identifies a population that may benefit from more aggressive cholesterol lowering, and evolocumab can be an important option when residual risk remains high.
Reference
Bergmark BA, Bohula EA, Marston NA, Park JG, Kuder JF, Murphy SA, De Ferrari GMM, Leiter LA, Nicolau JC, Averkov O, Charng MJ, Ebenbichler C, Erglis A, Gouni-Berthold I, Montalescot G, Nicholls SJ, Sigurdsson A, Sinnaeve P, Slapikas R, Tsioufis K, Verma S, Viigimaa M, Bhatia AK, Xin L, Walsh E, Ohman EM, Giugliano RP, Sabatine MS. Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial. Circulation. 2026-05-19. PMID: 42153665. https://pubmed.ncbi.nlm.nih.gov/42153665/